GILBOA UDI enters NASUS PHARMA LTD with 1.92M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Indirect Derivatives
Filed: 3/27/2026ACC: 0001493152-26-013383
1.92M
Baseline shares
100% direct
1.92M
Direct ownership
1 position
17.97K
Derivative underlying
1 instrument
2
Security positions
5.20K indirect
Non-Derivative Holdings2
Ordinary Shares
DirectShares owned1.92M
Ordinary Shares
IndirectShares owned5.20K
Total
1.92M direct·5.20K indirect1.92M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Ordinary Shares | 1.92M | Direct |
| Ordinary Shares | 5.20K | Indirect |
| Total | 1.92M | 1.92M direct·5.20K indirect |
Derivative Holdings1
Warrants
DirectUnderlying security
Ordinary Shares
Underlying shares
17.97K
Shares owned
N/A
Exercise price
6.53
Expiration
—
Exercise window
—
Total
Underlying
17.97K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Warrants Direct | Ordinary Shares | 6.53 | — | — | 17.97K | N/A |
| Total | 17.97K | 0.00 | ||||